1. Market Research
  2. > Community-Acquired Infections - Pipeline Review, H2 2013

Community-Acquired Infections - Pipeline Review, H2 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 54 pages

Community-Acquired Infections - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Community-Acquired Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Community-Acquired Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Community-Acquired Infections. Community-Acquired Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Community-Acquired Infections.
- A review of the Community-Acquired Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Community-Acquired Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Community-Acquired Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Community-Acquired Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Community-Acquired Infections - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Community-Acquired Infections Overview 6
Therapeutics Development 7
Pipeline Products for Community-Acquired Infections - Overview 7
Pipeline Products for Community-Acquired Infections - Comparative Analysis 8
Community-Acquired Infections - Therapeutics under Development by Companies 9
Community-Acquired Infections - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Community-Acquired Infections - Products under Development by Companies 14
Community-Acquired Infections - Companies Involved in Therapeutics Development 15
Ranbaxy Laboratories Limited 15
Debiopharm International S.A. 16
Implicit Bioscience Limited 17
Tetraphase Pharmaceuticals Inc. 18
TechnoPhage SA 19
Melinta Therapeutics Inc. 20
Community-Acquired Infections - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Assessment by Therapeutic Class 30
Drug Profiles 33
eravacycline - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
RX-02 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
RBx-14255 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
TP-112 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
TP-106 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
TP-107 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Debio-1348 - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
oglufanide disodium - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Community-Acquired Infections - Recent Pipeline Updates 43
Community-Acquired Infections - Dormant Projects 46
Community-Acquired Infections - Discontinued Products 47
Community-Acquired Infections - Product Development Milestones 48
Featured News and Press Releases 48
Apr 29, 2013: Tetraphase Pharma Presents Data Supporting Efficacy Of Eravacycline Against Multi-Drug Resistant Infections At ECCMID 2013 48
Sep 05, 2012: Tetraphase Pharma To Present New Clinical And Preclinical Research On Antibiotic Portfolio At ICAAC 2012 48
Apr 13, 2012: Cempra To Present Overview On Solithromycin At Future Leaders In Biotechnology Industry Conference 49
Mar 28, 2012: Paratek Wins Agreement With FDA On Special Protocol Assessment For Phase III Study In Community-Acquired Bacterial Pneumonia 49
Sep 15, 2011: Cempra Announces Comparable Efficacy Of Oral Solithromycin Compared With Levofloxacin In Phase II Clinical Trial In Patients With Community-Acquired Bacterial Pneumonia 50
Oct 29, 2010: Pfizer Canada Introduces PrZmax SR 51
Apr 29, 2003: FDA Approves Use of ZOSYN in a More Convenient Regimen. 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54



List of Tables

Number of Products under Development for Community-Acquired Infections, H2 2013 7
Number of Products under Development for Community-Acquired Infections - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Stage Development, H2 2013 12
Comparative Analysis by Unknown Stage Development, H2 2013 13
Products under Development by Companies, H2 2013 14
Community-Acquired Infections - Pipeline by Ranbaxy Laboratories Limited, H2 2013 15
Community-Acquired Infections - Pipeline by Debiopharm International S.A., H2 2013 16
Community-Acquired Infections - Pipeline by Implicit Bioscience Limited, H2 2013 17
Community-Acquired Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2013 18
Community-Acquired Infections - Pipeline by TechnoPhage SA, H2 2013 19
Community-Acquired Infections - Pipeline by Melinta Therapeutics Inc., H2 2013 20
Assessment by Monotherapy Products, H2 2013 21
Number of Products by Stage and Target, H2 2013 23
Number of Products by Stage and Mechanism of Action, H2 2013 25
Number of Products by Stage and Route of Administration, H2 2013 27
Number of Products by Stage and Molecule Type, H2 2013 29
Number of Products by Stage and Therapeutic Class, H2 2013 32
Community-Acquired Infections Therapeutics - Recent Pipeline Updates, H2 2013 43
Community-Acquired Infections - Dormant Projects, H2 2013 46
Community-Acquired Infections - Discontinued Products, H2 2013 47



List of Figures

Number of Products under Development for Community-Acquired Infections, H2 2013 7
Number of Products under Development for Community-Acquired Infections - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Early Stage Products, H2 2013 12
Assessment by Monotherapy Products, H2 2013 21
Number of Products by Top 10 Target, H2 2013 22
Number of Products by Stage and Top 10 Target, H2 2013 23
Number of Products by Top 10 Mechanism of Action, H2 2013 24
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 25
Number of Products by Top 10 Route of Administration, H2 2013 26
Number of Products by Stage and Top 10 Route of Administration, H2 2013 27
Number of Products by Top 10 Molecule Type, H2 2013 28
Number of Products by Stage and Top 10 Molecule Type, H2 2013 29
Number of Products by Top 10 Therapeutic Class, H2 2013 30
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 31



Companies Mentioned

Ranbaxy Laboratories Limited
Debiopharm International S.A.
Implicit Bioscience Limited
Tetraphase Pharmaceuticals Inc.
TechnoPhage SA
Melinta Therapeutics Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.